Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal.

The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain its profitability and signaled an interest in new business development opportunities in its core focus areas of CNS and oncology (see "Alkermes Restructures”).

On Monday,

Read the full 586 word article

User Sign In